NSE-listed companies offering contract development and manufacturing (CDMO) services or active pharmaceutical ingredient (API) production, positioned to benefit from global supply chain diversification away from China.
Sectors represented: Healthcare
RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. . Risingshareofbiologicsalongwithincreasinginvestmentsin ent. . RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. .
Pharmaceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years. aceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years.
India remains a major supplier of affordable generic medicines worldwide and has the highest number of USFDA-compliant pharmaceutical. manufacturing facilities outside the United States. Pharmaceutical exports reached approximately Rs. generic medicines worldwide and has the highest number of USFDA-compliant pharmaceutical. manufacturing facilities outside the United States.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
DCGI approvals. 1. , along with. 923 FSSAI approvals. 150. 4. 925+. 3. (1) As of 31st March 2024; (2) As of 1st Aug 2024. Domestic Branded Formulations. 59. th. Rank in Indian Branded. Formulations. 1. 140. Brands. 69%. Chronic and. sub-chronic segment. 1. 1.5k+. Salesforce. Exports Oriented Branded Formulations. 179. 246. 134. 289. Mar’22Mar’23Mar’24. Under Registration. Dossiers.
Manufacturing Organisation (CDMO) industry is experiencing. strong growth, driven by increasing outsourcing by. pharmaceutical and biotechnology companies and rising ntract Development and. Manufacturing Organisation (CDMO) industry is experiencing. strong growth, driven by increasing outsourcing by. pharmaceutical and biotechnology companies and rising.
The global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued. at US$166.0 Billion in 2025 and projected to reach US$293.6 Billion global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued.
Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3. 5.0. 5.6. 6.2. 7.1. 8.2. 9.5. 10.8 920242029F. Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3.
High-Potency APIs (HPAPIs). HPAPIs represent one of the most technically. demanding API segments. edibility a key. differentiator influencing supplier selection and. contract longevity. . High-Potency APIs (HPAPIs). HPAPIs represent one of the most technically. demanding API segments. The HPAPI market is. projected to grow from ~USD 30 billion in 2025 to. ~USD 48.3 billion by 2033. [6].. .
Steroidsproducts. ❏HPAPIsdevelopmentandmanufacturing. ❏USFDAapprovedmanufacturingfacilityfor. upcomingAPIs. ❏Flowchemistryfromlabtomanufacturing. ❏CompleteCMCdocumentationsupport. Xanthine derivatives & Intermediates. (Caffeine and others). ❏LargestIndianManufacturerforXanthine cturingfacilityfor. upcomingAPIs. ❏Flowchemistryfromlabtomanufacturing. ❏CompleteCMCdocumentationsupport.
Indian CDMO companies are increasingly. moving up the value chain from generic APIs to complex. molecules, biologics, and specialty services. ss, strong chemistry capabilities, and a large. talent pool. Indian CDMO companies are increasingly. moving up the value chain from generic APIs to complex. molecules, biologics, and specialty services. Growth is being.
This quality upgrade. cycle, though challenging for. smaller units, is fundamentally. strengthening India's credibility. as a globally trusted, regulation-. compliant API supplier a critical. competitive advantage as. regulated market buyers tighten. supplier qualification standards. 7.74%. CAGR. 14.2. 2025. 15.3. 2026. 22.3. 2031. Growth by Market Segment.
Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as. formulations Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as.
Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg. ACITIES. CLOSE PROXIMITY. TO CLIENTS WITH. GLOBAL PRESENCE. Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg.
Transplant & Immuno. Isacrest. TM. 18. Trusted CDMO partner for Fermentation & Semi-Synthetic API’s. CDMO Overview. Provide contract research and manufacturing. services for developing APIs and formulations. Prioritizes innovation, backed by a DSIR-. certified R&D facility with a team of 180+ tic API’s. CDMO Overview. Provide contract research and manufacturing.
Process DevelopmentQuality & Regulatory ServicesDrug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced. contamination risk and higher uptime. . Clinical batches to high-speed commercial. lines inc. ug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced.